financetom
Business
financetom
/
Business
/
Peloton shares jump as turnaround strategy gains traction
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Peloton shares jump as turnaround strategy gains traction
Nov 7, 2025 2:44 AM

(Reuters) -Peloton Interactive ( PTON ) shares jumped more than 7% in premarket trading on Friday after the fitness company beat quarterly revenue estimates, buoyed by early traction from its revamped product lineup and price hikes across hardware and subscriptions, reinforcing investor confidence in its turnaround strategy.

The upbeat results mark a turning point for Peloton under CEO Peter Stern, who took the helm in January and has focused on restoring profitability, streamlining operations, and repositioning the brand for growth through a refreshed product lineup and pricing strategy.

"We are encouraged by Peloton's progress across improving profit, ramping free cash flow, and deleveraging," J.P.Morgan analysts said. "But it remains to be seen whether product and marketing initiatives are significant enough to drive durable revenue growth."

Peloton recently re-launched its product portfolio with AI-powered features and raised prices across hardware and subscriptions and its move comes as shoppers pull-back spending on big-ticket discretionary items amid an unsteady economic environment.

The company reported revenue of $550.8 million for the quarter, topping analysts' average estimate of $539.82 million, as per data compiled by LSEG.

The stock trades at a price-to-earnings ratio of 79.95, reflecting expectations for continued earnings momentum.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Looking At Duke Energy's Recent Unusual Options Activity
Looking At Duke Energy's Recent Unusual Options Activity
Oct 15, 2024
Investors with a lot of money to spend have taken a bullish stance on Duke Energy ( DUK ) . And retail traders should know. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this...
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Oct 15, 2024
Jazz Pharmaceuticals plc ( JAZZ ) revealed topline results from the Phase 3 clinical trial evaluating Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor Roche Holdings AG’s (OTC:RHHBY) atezolizumab (Tecentriq) compared to atezolizumab alone when administered as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of Zepzelca and atezolizumab showed...
Update: Market Chatter: Dell to Start Shipping Servers With New Nvidia AI Chips in November
Update: Market Chatter: Dell to Start Shipping Servers With New Nvidia AI Chips in November
Oct 15, 2024
11:50 AM EDT, 10/15/2024 (MT Newswires) -- (Updates with Nvidia's ( NVDA ) response in the third paragraph.) Dell Technologies ( DELL ) will start shipping servers featuring Nvidia's ( NVDA ) Blackwell artificial intelligence accelerators to select customers next month, Bloomberg reported Tuesday, citing an interview with Arthur Lewis, Dell's infrastructure unit president. The servers containing the Blackwell chips...
BriaCell to Complete Patient Enrollment for Phase 3 Breast Cancer Study by Mid-2025; Shares Rise
BriaCell to Complete Patient Enrollment for Phase 3 Breast Cancer Study by Mid-2025; Shares Rise
Oct 15, 2024
11:49 AM EDT, 10/15/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Tuesday that patient enrollment for its pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer is on track for expected completion by mid-2025. The trial aims to enroll up to 354 patients, randomized 1:1 to receive either the BriaCell...
Copyright 2023-2026 - www.financetom.com All Rights Reserved